Kumamaru H, Takeuchi Y, Kohsaka S, Matsui H, Yasunaga H, Miyata H. Comparative effectiveness of First-line SGLT2 inhibitor use on heart failure hospitalization among patients with type 2 diabetes mellitus; A target trial emulation (Poster presentation). 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 2022 Aug, Copenhagen/Online.
Takeuchi Y, Iwagami M, Ono S, Yasunaga H. Serious adverse effects after COVID-19 vaccination in Japan: Analysis using administrative claims data linked with vaccination registry. 14th Asian Conference on Pharmacoepidemiology. 2022 Oct, Tainan/Online.
Sawamoto R, Matsuyama Y. Standardized mortality ratio-weighted power prior approach for covariate-adjusted borrowing of historical control data. 2021 Joint Statistical Meetings, Online. Aug 2021.
Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
Sakamoto A, Aizawa K, Uemura K, Komuro I, Matsuyama Y, Nagai R. Increased serum immunoglobulin G4 level is a novel predictor of cardiovascular events independent of established risk factors: Results from the REAL-CAD study. American Heart Association Scientific Sessions 2020 November 14-16, Dallas, Texas
Hagiwara Y, Kawahara T, Shiroiwa T. What is a valid mapping algorithm in cost-utility analyses? An answer from a missing data perspective. International Society for Pharmacoeconomics and Outcome Research Europe 2019. Copenhergen, Denmark. November 2019. PNS323.
Kashiwabara K, Matsuyama Y. Treatment effect estimation in an efficient adaptive design: comparison with the exact estimation method. 40th Annual Conference of the ISCB 2019, 14-18 July, Leuven, Belgium.
Satoi S, Unno M, Motoi F, Matsuyama Y, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, Yoshitomi H, Takahashi S, Sho M, Ueno H, Yamamoto H, Kosuge T. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (Randomized phase II/III trial; Prep-02/JSAP-05). ASCO 2019, May 31-June 4, Chicago, USA
Izumi N, Hasegawa K, Nishioka Y, Takayama T, Yamanaka N, Kudo M, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). ASCO 2019, May 31-June 4, Chicago, USA. J Clin Oncol 37, 2019 (suppl; abstr 4002)
Matsumoto I, Unnno M, Motoi F, Satoi S, Aosasa S, Shirakawa H, Wada K, Matsuyama Y. The feasibility and efficacy of neoadjuvant chemotherapy for resectable pancreatic cancer: A randomized phase II/III trial from Japan. 48th World Congress of Surgery WCS 2019, Krakow, Poland, 14 August 2019.
Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial. San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
Kashiwabara K, Matsuyama Y. Point and interval estimation in an efficient adaptive design of flexible sample size determination. At: Joint International Society for Clinical Biostatistics and Australian Statistical Conference 2018, Melbourne, Australia, 26–30 August, 2018. Abstr P4.
Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M. The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy. International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference. Tokyo, Japan. September 2018. PCN65.
Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.